Drugs / TBAJ-587
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04890535 Comparator | Dec 2020 → Feb 2023 | tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBAJ-587 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04890535 ↗ |
| Known as | telacebec | “Telacebec (T) is a novel cytochrome bc1:aa3 oxidase inhibitor that also inhibits ATP synthesis.” PMID 39651910 ↗ Dec 2024 |
| Modality | Small molecule | “TBAJ-587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies.” PMID 41255184 ↗ Nov 2025 |